Search

Background: There is a paucity of data on biomarker testing rates in rural populations with metastatic colorectal cancer (mCRC). To assess biomarker testing practices, oncologists in rural areas and urban clusters in the US were surveyed. Materials and Methods: A web-based survey was administered to oncologists spending ≥40% of their time practicing in rural areas or urban clusters and who had treated ≥2 patients with stage IV mCRC in the prior month. Results: Ninety-nine oncologists completed the quantitative survey and 17 the qualitative interview. Among respondents, 97% reported ordering biomarker tests. Oncologists reported testing for KRAS, NRAS, BRAF, HER2, and mismatch repair deficiency/microsatellite instability in 72%, 65%, 63%, 56%, and 66% of patients with metastatic disease, respectively. Forty-one percent reported performing reflex testing. The most cited testing barriers were lack of insurance coverage, insufficient tissue samples, and long turnaround times. Conclusion: Further assessment of rural testing practices is needed. In this study, oncologists in the US were surveyed to investigate practice patterns related to biomarker testing in rural areas and urban clusters, uncover obstacles to biomarker testing, and understand the role of telehealth in metastatic colorectal cancer. [ABSTRACT FROM AUTHOR]

In oncology practices across the United States, biosimilars-highly similar versions of licensed, innovator (reference) biological medicines-are currently emerging as more affordable therapeutic options. Only after a rigorous product development program, during which a proposed biosimilar is analyzed and compared with its reference biologic to demonstrate comparable clinical efficacy, safety, and tolerability, is biosimilarity supported and licensure granted by the US Food and Drug Administration. Coincidentally, many advanced practitioners (APs) are finding themselves at the forefront of introducing monoclonal antibody (mAb) biosimilars in their oncology practice. Advanced practitioners are often tasked with building the confidence of colleagues and patients who may be unfamiliar with biosimilars, skeptical about integrating them, or have yet to consider mAb biosimilars as a viable and more sustainable cancer treatment option. With this responsibility comes a number of challenges that require APs to become knowledgeable about biosimilars and approaches to their implementation. This review aims to highlight the practical implications of streamlining the integration of biosimilar therapies in an oncology practice., Competing Interests: Dr. Mayden has received payment for service on speakers bureaus from Pfizer, Amgen, and Puma outside the submitted work. Dr. McBride has received payment from Pfizer and Amgen for consultancy work, and payment for lectures including service on speakers bureaus from Pfizer and Coherus, all outside the submitted work. Dr. Kelton and Dr. Ryan are full-time employees of and hold stock or options in Pfizer Inc., (© 2022 Harborside™.)